Tirzepatide vs MOTS-c
Head-to-head comparison of Tirzepatide and MOTS-c for research applications. Both peptides are studied for Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Tirzepatide | Mots C |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Metabolic / Mitochondrial |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. | MOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). |
| Evidence Rating | A — FDA Approved | D — Preclinical |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | Research-only / No human clinical trials completed (Phase 1 of analog CB4211 only) |
| Safety Profile | Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting; Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems | No adverse effects reported in preclinical animal studies; Human tolerability is completely unknown for native MOTS-c (no completed human trials) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 2.5–15 mg/week, titrated every 4 weeks | 5–10 mg SC per injection |
| Frequency | Once weekly | Once daily or 3–5x weekly |
| Molecular Weight | ~4813.5 g/mol | ~2174.6 g/mol |
| Half-Life | ~5 days (116 hours) | Several hours; tissue effects may persist longer |
Overview
Tirzepatide and MOTS-c are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Tirzepatide — Mechanism & Evidence
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.
Key claims: Superior weight loss compared to semaglutide; Improves blood sugar control; May improve liver fat / NASH.
Tirzepatide 10mg
10mg
BPC-157 5mg
5mg
MOTS-c — Mechanism & Evidence
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.
Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.
Shared Research Applications
Both peptides are studied for: Metabolic Health.
Tirzepatide is also researched for: Weight Management.
MOTS-c is also researched for: Anti-Aging.
Safety Considerations
Tirzepatide: Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath
MOTS-c: No adverse effects reported in preclinical animal studies Human tolerability is completely unknown for native MOTS-c (no completed human trials) Modified analog CB4211 showed good tolerability in Phase 1
Shop Research Peptides
Tirzepatide 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
MOTS-c Half-Life: What Studies Show and What Remains Unknown
This reference clarifies what primary studies have established about MOTS-c half-life and stability, and identifies the pharmacokinetic questions that remain unanswered in humans.
Tirzepatide vs Retatrutide: Evidence, Mechanisms, Safety
This reference distinguishes randomized trial evidence from extrapolation for tirzepatide and retatrutide, clarifying mechanisms and safety. It highlights the absence of direct head-to-head trials and the limits of current data.
Tirzepatide Tied to Reduced Heart Attack Risk in High-Risk Patients
A recent report highlights that the GLP-1 drug tirzepatide is associated with a lower risk of heart attacks in patients considered high-risk. The finding adds to growing evidence of cardiovascular benefits for this class of medications. Details from the WDBJ7 report are summarized here.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe